1046045-58-2

Upstream product

• 125256-03-3 4-(4-(4-bromophenyl)thiazol-2-yl)-2-propylpyridine 
• 99-81-0 4-Nitrophenacyl bromide 
• 100-19-6 (4-nitrophenyl)ethanone 
• 33744-19-3 2-propylpyridine-4-carbonitrile 
• 100-48-1 pyridine-4-carbonitrile 
• 14222-60-7 prothionamide 
• 1046045-78-6 C₃₀H₂₅N₃S 

Downstream Products

• 1046045-73-1 tert-butyl 4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenylcarbamate 
• 1046045-79-7 dansyl fatostatin 
• 1046045-82-2 4-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenylamino)-N-isopropylbutanamide 
• 1046045-81-1 C₂₆H₃₁N₃O₄S 
• 1046045-80-0 C₂₈H₃₅N₃O₄S 
• 1046045-83-3 C₂₉H₃₈N₄O₃S 
• 1046045-63-9 N-(cyclopropylmethyl)-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)aniline 
• 1046045-59-3 N-isopropyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)benzenamine 
• 1046045-75-3 4-methyl-N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)benzenesulfonamide 
• 1046045-60-6 N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)acetamide 
• 1046045-61-7 N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)methanesulfonamide 
• 1046045-62-8 N-benzyl-4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)aniline 
• 1046045-77-5 N-(4-(2-(2-propylpyridin-4-yl)thiazol-4-yl)phenyl)thiophene-2-sulfonamide 

Relevant academic research and scientific papers

SYNTHESIS OF FATOSTATIN BASED POLYCYCLIC COMPOUNDS

The present invention relates to methods and strategies for large-scale synthesis of compounds having the chemical structure: (I). The R substituents are H, methyl, isopropyl, benzyl, cyclohexyl, cyclopropylmethyl, methoxy, tert-butyloxycarbonyl, methanes

Diarylthiazole: An antimycobacterial scaffold potentially targeting PrrB-PrrA two-component system

Diarylthiazole (DAT), a hit from diversity screening, was found to have potent antimycobacterial activity against Mycobacterium tuberculosis (Mtb). In a systematic medicinal chemistry exploration, we demonstrated chemical opportunities to optimize the potency and physicochemical properties. The effort led to more than 10 compounds with submicromolar MICs and desirable physicochemical properties. The potent antimycobacterial activity, in conjunction with low molecular weight, made the series an attractive lead (antibacterial ligand efficiency (ALE) >0.4). The series exhibited excellent bactericidal activity and was active against drug-sensitive and resistant Mtb. Mutational analysis showed that mutations in prrB impart resistance to DAT compounds but not to reference drugs tested. The sensor kinase PrrB belongs to the PrrBA two component system and is potentially the target for DAT. PrrBA is a conserved, essential regulatory mechanism in Mtb and has been shown to have a role in virulence and metabolic adaptation to stress. Hence, DATs provide an opportunity to understand a completely new target system for antimycobacterial drug discovery.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.